Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Chemotherapy and Surgery for Adrenocortical Carcinoma
NCT00001339Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 1993
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mitotane, doxorubicin, vincristine and etoposide in adrenocortical carcinoma (ACC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Tumor Response and Therapeutic Efficacy. Started Aug 1993; status: completed.
02
Drugs
mitotanedoxorubicinvincristineetoposide
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT00001339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001339.